Univariate analysis for OS (censored for SCT)
| Variable . | Events/N (%) . | Median (mo) . | Log-rank . | HR (95% confidence interval) . | P value . |
|---|---|---|---|---|---|
| Age, continuous, y | 226 of 635 (35.6) | 18.4 | — | 1.03 (1.02-1.03) | < .001 |
| Age, categorical, y | <0.001 | ||||
| <60 | 96 of 338 (28.4) | 33.5 | 1.00 | — | |
| ≥60 | 130 of 297 (43.8) | 13.7 | 1.69 (1.29-2.21) | < .001 | |
| Sex | 0.750 | ||||
| Male | 122 of 323 (37.8) | 21.7 | 1.00 | — | |
| Female | 104 of 312 (33.3) | 15.8 | 1.04 (0.80-1.36) | .750 | |
| Treatment intensity | <0.001 | ||||
| IA | 109 of 385 (28.3) | 27.8 | 1.00 | — | |
| LOW + VEN | 117 of 250 (46.8) | 12.4 | 1.96 (1.50-2.57) | < .001 | |
| Best response | <0.001 | ||||
| CR | 168 of 534 (31.5) | 25.1 | 1.00 | — | |
| CRi | 41 of 76 (53.9) | 8.3 | 2.29 (1.62-3.22) | < .001 | |
| MLFS | 17 of 25 (68) | 7.1 | 3.60 (2.18-5.95) | < .001 | |
| MRD status | <0.001 | ||||
| Negative | 122 of 426 (28.6) | 35.4 | 1.00 | — | |
| Positive | 104 of 209 (49.8) | 8.9 | 2.38 (1.83-3.10) | < .001 | |
| ELN 2017 risk | <0.001 | ||||
| Favorable | 41 of 161 (25.5) | 80.9 | 1.00 | — | |
| Intermediate | 57 of 190 (30) | 25.5 | 1.32 (0.88-1.97) | .178 | |
| Adverse | 125 of 273 (45.8) | 9.4 | 3.00 (2.10-4.28) | < .001 | |
| Cytogenetics∗ | |||||
| Diploid | 82 of 307 (26.7) | 39.2 | — | 1.00 | — |
| Other intermediate | 33 of 100 (33) | 26.6 | 0.134 | 1.36 (0.91-2.04) | .136 |
| 11q23 | 13 of 34 (38.2) | 6.4 | <0.001 | 3.27 (1.79-5.96) | < .001 |
| t(6;9) | 0 of 8 (0) | Not reached | 0.102 | 0.00 (0.00-NE) | .999 |
| inv(3) | 7 of 10 (70) | 8.7 | <0.001 | 3.88 (1.77-8.50) | .001 |
| −5/5q– | 46 of 76 (60.5) | 7.4 | <0.001 | 4.24 (2.91-6.19) | < .001 |
| −7/7q– | 39 of 70 (55.7) | 7.8 | <0.001 | 4.08 (2.74-6.05) | < .001 |
| −17/17p– | 30 of 52 (57.7) | 7.9 | <0.001 | 3.71 (2.41-5.70) | < .001 |
| Complex | 77 of 136 (56.6) | 7.4 | <0.001 | 3.84 (2.78-5.30) | < .001 |
| Variable . | Events/N (%) . | Median (mo) . | Log-rank . | HR (95% confidence interval) . | P value . |
|---|---|---|---|---|---|
| Age, continuous, y | 226 of 635 (35.6) | 18.4 | — | 1.03 (1.02-1.03) | < .001 |
| Age, categorical, y | <0.001 | ||||
| <60 | 96 of 338 (28.4) | 33.5 | 1.00 | — | |
| ≥60 | 130 of 297 (43.8) | 13.7 | 1.69 (1.29-2.21) | < .001 | |
| Sex | 0.750 | ||||
| Male | 122 of 323 (37.8) | 21.7 | 1.00 | — | |
| Female | 104 of 312 (33.3) | 15.8 | 1.04 (0.80-1.36) | .750 | |
| Treatment intensity | <0.001 | ||||
| IA | 109 of 385 (28.3) | 27.8 | 1.00 | — | |
| LOW + VEN | 117 of 250 (46.8) | 12.4 | 1.96 (1.50-2.57) | < .001 | |
| Best response | <0.001 | ||||
| CR | 168 of 534 (31.5) | 25.1 | 1.00 | — | |
| CRi | 41 of 76 (53.9) | 8.3 | 2.29 (1.62-3.22) | < .001 | |
| MLFS | 17 of 25 (68) | 7.1 | 3.60 (2.18-5.95) | < .001 | |
| MRD status | <0.001 | ||||
| Negative | 122 of 426 (28.6) | 35.4 | 1.00 | — | |
| Positive | 104 of 209 (49.8) | 8.9 | 2.38 (1.83-3.10) | < .001 | |
| ELN 2017 risk | <0.001 | ||||
| Favorable | 41 of 161 (25.5) | 80.9 | 1.00 | — | |
| Intermediate | 57 of 190 (30) | 25.5 | 1.32 (0.88-1.97) | .178 | |
| Adverse | 125 of 273 (45.8) | 9.4 | 3.00 (2.10-4.28) | < .001 | |
| Cytogenetics∗ | |||||
| Diploid | 82 of 307 (26.7) | 39.2 | — | 1.00 | — |
| Other intermediate | 33 of 100 (33) | 26.6 | 0.134 | 1.36 (0.91-2.04) | .136 |
| 11q23 | 13 of 34 (38.2) | 6.4 | <0.001 | 3.27 (1.79-5.96) | < .001 |
| t(6;9) | 0 of 8 (0) | Not reached | 0.102 | 0.00 (0.00-NE) | .999 |
| inv(3) | 7 of 10 (70) | 8.7 | <0.001 | 3.88 (1.77-8.50) | .001 |
| −5/5q– | 46 of 76 (60.5) | 7.4 | <0.001 | 4.24 (2.91-6.19) | < .001 |
| −7/7q– | 39 of 70 (55.7) | 7.8 | <0.001 | 4.08 (2.74-6.05) | < .001 |
| −17/17p– | 30 of 52 (57.7) | 7.9 | <0.001 | 3.71 (2.41-5.70) | < .001 |
| Complex | 77 of 136 (56.6) | 7.4 | <0.001 | 3.84 (2.78-5.30) | < .001 |
HR, hazard ratio.
HRs are for individual cytogenetic features compared with diploid as the baseline risk.